NeuroPace issued a press release on May 27, 2025, “announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).” The press release disclosed that “[t]he study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group.”
Following this news, NeuroPace’s stock price fell over 28% on the same day.
To receive more information, please fill out the form.
